PRPS1/PRPS2/PRPS3 Antibody (C-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P60891 |
---|---|
Other Accession | Q5JV75 |
Clone Names | 4012121 |
Gene ID | 5631 |
---|---|
Other Names | Ribose-phosphate pyrophosphokinase 1, PPRibP, Phosphoribosyl pyrophosphate synthase I, PRS-I, PRPS1 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP7178a was selected from the C-term region of human PRPS1/2/3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | PRPS1 (HGNC:9462) |
---|---|
Function | Catalyzes the synthesis of phosphoribosylpyrophosphate (PRPP) that is essential for nucleotide synthesis. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Phosphoribosylpyrophosphate synthetase (PRPS) catalyzes the phosphoribosylation of ribose 5-phosphate to 5-phosphoribosyl-1-pyrophosphate, which is necessary for the de novo and salvage pathways of purine, pyrimidine, and pyridine biosynthesis. Defects in PRPS1 are the cause of PRPS-related gout, also known as gout due to PRPS1 superactivity. It is a familial disorder characterized by excessive purine production, gout and uric acid urolithiasis.
References
Ahmed, M., et al., J. Biol. Chem. 274(11):7482-7488 (1999).Ishijima, S., et al., Biochim. Biophys. Acta 1342(1):28-36 (1997).Becker, M.A., et al., J. Biol. Chem. 271(33):19894-19899 (1996).Roessler, B.J., et al., J. Biol. Chem. 268(35):26476-26481 (1993).Ishizuka, T., et al., Biochim. Biophys. Acta 1130(2):139-148 (1992).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.